Why is the ResMed share price taking a thumping on Thursday?

Investors seem to be signalling out ResMed for punishment.

| More on:
Shot of a scientist using a computer while conducting research in a laboratory.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

It's been a fairly miserable Thursday session for ASX shares so far today. At the time of writing, the S&P/ASX 200 Index (ASX: XJO) has slipped by 0.04% and is back under 8,140 points. But let's talk about what's going on with the ResMed CDI (ASX: RMD) share price.

Whilst the ASX 200 is having a bad day, it's been far worse for Resmed shares. This ASX 200 healthcare stock closed at $36.25 a share yesterday. But this morning, those same shares opened at just $35.30 and are now down a painful 3.5% at $34.98 each.

So why is the Resmed share price getting such a dramatic hammering this session?

What's up with the ResMed share price today?

Well, it's hard to know for sure. There haven't been any fresh developments or news out of Resmed itself today on the ASX.

But there are still a few things we can point out.

Firstly, it's been a pretty rough day for most ASX healthcare stocks. The healthcare sector is currently the third-worst performing sector on the markets, with the S&P/ASX 200 Health Care Index (ASX: XHJ) currently down 0.65%.

Other healthcare shares, such as CSL Ltd (ASX: CSL), Polynovo Ltd (ASX: PNV), and Cochlear Ltd (ASX: COH), are also suffering today.

Secondly, Resmed's US-listed stock ResMed Inc (NYSE: RMD) also had a pretty bad night last night. Resmed has a dual-listed structure, meaning its shares can be found both on the Australian market and on the New York Stock Exchange. The American shares often set the tone for what happens on the ASX.

Last night, Resmed's American share price had a shocker, falling 5.12% to US$238.03 a share.

Our Fool colleagues over in the States posited that this fall might be a result of a broker downgrade. Wolfe Research's Mike Polark reportedly moved Resmed shares from a hold to a sell.

Resmed gets a sell rating

He also gave the company a 12-month share price target of US$180 per share, which, if accurate, would see the company lose a quarter of its value from current levels.

Polark's pessimism stems from concerns that Resmed might be poised to lose market share to its pharmaceutical rival Eli Lilly. He argued that "disruption risks to RMD's business rise in 2025-2026 due to Lilly's likely launch of an obstructive sleep apnea indication for its GLP-1 medication tirzepatide".

So that might have been what tanked Resmed's US stock last night, and thus indirectly responsible for today's poor ASX showing from the Resmed share price.

Despite today's sell-off, Resmed's ASX shares remain up a robust 37.7% in 2024 and 53.9% over the past 12 months.

Motley Fool contributor Sebastian Bowen has positions in CSL. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL, Cochlear, PolyNovo, and ResMed. The Motley Fool Australia has positions in and has recommended ResMed. The Motley Fool Australia has recommended CSL, Cochlear, and PolyNovo. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Overjoyed man celebrating success with yes gesture after getting some good news on mobile.
Healthcare Shares

Telix shares jump 7% on big US news

Let's see what is getting investors excited on Wednesday.

Read more »

An older gentleman leans over his partner's shoulder as she looks at a tablet device while seated at a table.
Healthcare Shares

Macquarie tips 28% upside for this ASX healthcare stock

The broker expects big things from this New Zealand retirement village developer and operator.

Read more »

Teamwork, planning and meeting with doctors and laptop for medical, review and healthcare. Medicine, technology and internet with group of people for collaboration, diversity and support in hospital
Healthcare Shares

$10,000 invested in these ASX healthcare shares 5 years ago is now worth…

These healthcare stocks have brought big returns for investors 

Read more »

A man wearing a white coat and glasses is wide-mouthed in surprise.
Healthcare Shares

Guess which ASX 300 stock is crashing 55% today

What's going on with this stock? Let's see why investors are hitting the sell button.

Read more »

Woman serving customer in pharmacy.
Healthcare Shares

Up 132% in a year, are Sigma Healthcare shares still a good buy post the Chemist Warehouse merger?

After gaining 132% in 12 months, it too late to buy Sigma Healthcare shares today?

Read more »

Three scientists wearing white coats and blue gloves dance together in a lab.
Share Market News

Is it too late to buy Pro Medicus shares?

Pro Medicus shares have risen 550% over 3 years. Have you missed the boat? Three experts weigh in.

Read more »

Researchers and doctors with futuristic 3d hologram overlay for body anatomy or dna in hospital clinic.
Healthcare Shares

These 5 ASX 200 healthcare shares gained the most weight in FY25

These stocks were in great health last financial year.

Read more »

Scientists working in the laboratory and examining results.
Healthcare Shares

Guess which ASX 300 healthcare stock is charging higher on product launch news

Investors have responded positively to this announcement.

Read more »